How to Reconstitute CJC-1295: Dosing Math (mg, mL, IU, Units)

What Is CJC-1295 and Why Does Reconstitution Math Matter?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that binds the GHRH receptor on pituitary somatotrophs and stimulates pulsatile growth hormone (GH) secretion. It is available in two principal forms: CJC-1295 without DAC (Drug Affinity Complex), which mirrors the natural GHRH pulse and clears in roughly 30 minutes, and CJC-1295 with DAC, which binds albumin and extends the half-life to approximately 6 to 8 days. Teichman et al. (2006, N=65) demonstrated that a single 2 mg/kg dose of CJC-1295 with DAC elevated mean plasma GH levels 2 to 10-fold for up to 6 days and raised IGF-1 by 26 to 49% over 28 days. [1]

Incorrect reconstitution math is the most common source of dosing errors with compounded peptides. Too little diluent produces a dangerously concentrated solution; too much diluent forces patients to inject inconveniently large volumes subcutaneously. Getting the arithmetic right the first time protects both efficacy and safety.

How CJC-1295 Is Supplied

Most compounding pharmacies operating under USP Chapter 797 guidelines dispense CJC-1295 as a sterile lyophilized (freeze-dried) white powder in sealed, crimp-top glass vials. Vial sizes of 2 mg, 5 mg, and 10 mg are typical. Because no FDA-approved finished drug product exists for CJC-1295, all clinical use relies on compounded preparations, which must meet USP 797 sterility and beyond-use dating requirements. [2]

Why the DAC Modification Changes Your Dosing Schedule

The DAC modification covalently links the peptide to a maleimide group that reacts with circulating albumin, dramatically extending circulating time. CJC-1295 without DAC is dosed at every injection session (often nightly alongside a GHRP such as ipamorelin), while CJC-1295 with DAC is dosed once or twice weekly. The reconstitution volume you choose should reflect this: a smaller diluent volume (producing a higher concentration) is convenient for less frequent dosing, whereas a larger volume allowing finer unit increments suits daily micro-dosing protocols.

The Core Reconstitution Formula

The single calculation every patient and clinician must internalize is:

Concentration (mg/mL) = Vial content (mg) ÷ Diluent added (mL)

From concentration, all syringe volumes follow automatically.

Step-by-Step Example: 2 mg Vial with 2 mL BWI

1. Peptide in vial: 2 mg (= 2,000 mcg)
2. Bacteriostatic water added: 2 mL
3. Resulting concentration: 2 mg ÷ 2 mL = 1 mg/mL (1,000 mcg/mL)
4. Desired dose: 200 mcg
5. Volume to inject: 200 mcg ÷ 1,000 mcg/mL = 0.20 mL
6. On a U-100 syringe: 0.20 mL × 100 units/mL = 20 units

That single chain of division produces the syringe reading. Write it on a sticky note and keep it with your vial.

Reconstitution Table: Common Vial Sizes and Diluent Volumes

| Vial Size | BWI Added | Concentration | 100 mcg dose | 200 mcg dose | 300 mcg dose | |-----------|-----------|---------------|--------------|--------------|--------------| | 2 mg | 1 mL | 2 mg/mL | 5 units | 10 units | 15 units | | 2 mg | 2 mL | 1 mg/mL | 10 units | 20 units | 30 units | | 5 mg | 2.5 mL | 2 mg/mL | 5 units | 10 units | 15 units | | 5 mg | 5 mL | 1 mg/mL | 10 units | 20 units | 30 units | | 10 mg | 5 mL | 2 mg/mL | 5 units | 10 units | 15 units | | 10 mg | 10 mL | 1 mg/mL | 10 units | 20 units | 30 units |

The 1 mg/mL concentration is the most widely used in clinical practice because the 10-units-per-100-mcg relationship is easy to remember and easy to measure on any U-100 syringe.

Bacteriostatic Water: Why It Is Required

Bacteriostatic water for injection (BWI) contains 0.9% benzyl alcohol as a preservative. Benzyl alcohol suppresses microbial growth across the multi-week period you will be drawing from the same vial. Sterile water for injection (SWFI) contains no preservative and is suitable only for single-use reconstitution, after the first draw, any remaining solution must be discarded. Given that a 2 mg vial of CJC-1295 typically provides 10 to 20 doses, SWFI is not a practical choice. [3]

Sourcing and Storage of BWI

Purchase bacteriostatic water for injection from a licensed pharmacy or medical supplier in sealed multi-dose vials. The FDA requires that BWI for injection meet specifications in USP monograph standards, including endotoxin limits and sterility testing. [4] Store unopened BWI at room temperature (15 to 30 °C) and discard any vial showing particulate matter or cloudiness.

What Never to Use as a Diluent

Tap water, distilled water, saline from a sports-medicine dropper bottle, and sodium chloride 0.9% irrigation (not injection-grade) are all inappropriate. Normal saline for injection (0.9% NaCl) is technically compatible but lacks benzyl alcohol preservation and shortens practical beyond-use time. Avoid it unless you plan single-use reconstitution.

Reconstitution Technique: Step-by-Step

Sterile technique is not optional. A single contamination event can introduce pyrogens or live bacteria directly into subcutaneous tissue.

Materials Checklist

• CJC-1295 lyophilized vial (refrigerated until use)
• Bacteriostatic water for injection, multi-dose vial
• Two 1 mL U-100 insulin syringes (one for transfer, one for injection)
• Alcohol swabs (70% isopropyl)
• Clean, flat work surface

The Reconstitution Procedure

1. Wash hands for 20 seconds with soap and water.
2. Swab both vial tops with separate alcohol swabs. Allow 30 seconds to air-dry. Do not blow on them.
3. Draw the target volume of BWI (e.g., 2 mL) into a larger syringe, or perform two draws of 1 mL each using a U-100 syringe if no larger syringe is available.
4. Insert the needle into the peptide vial at a 45-degree angle and let the BWI run slowly down the inside glass wall. Direct stream onto lyophilized cake disrupts peptide structure. [5]
5. Do not shake the vial. Roll it gently between your palms for 15 to 20 seconds until the powder dissolves completely. The solution should be clear and colorless.
6. Label the vial with the date, concentration (e.g., 1 mg/mL), and your initials.
7. Refrigerate immediately at 2 to 8 °C.

A 2006 stability study of synthetic GHRH analogs found that peptide integrity remained above 95% at 4 °C for 28 days when benzyl alcohol was present as a preservative, compared with a measurable degradation curve beginning at day 14 in preservative-free solutions. [6]

Drawing the Injection Dose: U-100 Syringe Unit Conversion

The U-100 syringe is calibrated for insulin, where 100 units = 1 mL. Peptide researchers and clinicians co-opt this syringe because it allows precise measurement of small subcutaneous volumes. No separate "IU" designation applies to CJC-1295, the word "units" here refers only to the syringe graduation marks, not to a biological potency unit.

Reading the Syringe

A standard U-100 syringe shows lines at every 2-unit interval (on a 0.3 mL syringe) or every 1-unit interval (on some 1 mL insulin syringes). At a concentration of 1 mg/mL:

• 10 units = 0.10 mL = 100 mcg
• 20 units = 0.20 mL = 200 mcg
• 30 units = 0.30 mL = 300 mcg

At a concentration of 2 mg/mL, every unit mark doubles in peptide content:

• 5 units = 0.05 mL = 100 mcg
• 10 units = 0.10 mL = 200 mcg
• 15 units = 0.15 mL = 300 mcg

Why Concentration Choice Matters for Precision

A 2 mg/mL solution compresses the dose range into very small volumes. On a 0.3 mL syringe with 2-unit markings, the difference between 100 mcg and 150 mcg is just 2.5 units, which can be difficult to read accurately. The 1 mg/mL solution doubles the measurable range and reduces relative measurement error, which is why most clinical protocols favor it for CJC-1295 without DAC.

Clinical Dosing Ranges and Protocols

No FDA-approved labeling governs CJC-1295 dosing. The following reflects the published clinical trial data and current compounding pharmacy prescribing practice reviewed by the HealthRX medical team.

CJC-1295 Without DAC (Short-Acting)

Typical doses range from 100 mcg to 300 mcg per injection. Most protocols combine this peptide with a growth hormone secretagogue (GHS) such as ipamorelin at an equal mcg dose, injected subcutaneously 30 to 60 minutes before sleep to align with the endogenous nocturnal GH pulse. Frequency ranges from 5 nights per week to nightly dosing over a 12-week cycle.

CJC-1295 With DAC (Long-Acting)

Teichman et al. (2006) used weight-based dosing (0.03 to 3 mg/kg) in their phase II trial. In clinical compounding practice, flat doses of 1 mg to 2 mg once weekly are most common, reflecting a balance between measurable IGF-1 elevation and tolerability. [1] At 2 mg once weekly from a 2 mg/mL reconstitution, the patient draws exactly 1 mL, 100 units on a U-100 syringe.

HealthRX Dosing Decision Framework: Choosing Your Concentration

Use this sequence when selecting diluent volume:

1. Identify your dose in mcg (e.g., 200 mcg).
2. Identify your syringe type (e.g., 0.3 mL U-100 with 2-unit increments).
3. Choose a concentration where your dose falls between 10 and 50 units on that syringe. This keeps measurement error below 5% while avoiding excessively small volumes.
4. If the dose falls below 5 units at any practical concentration, consider a lower-volume syringe (e.g., 0.5 mL, 50-unit capacity with 1-unit markings).
5. Confirm the math: (Dose in mcg ÷ 1,000) ÷ Concentration in mg/mL = Volume in mL. Multiply by 100 for units.

Injection Technique for Subcutaneous Administration

Subcutaneous injection places the peptide into the adipose layer directly beneath the skin, where it absorbs at a predictable rate. Intramuscular injection is not standard for CJC-1295 and provides no pharmacokinetic advantage.

Site Selection and Rotation

Appropriate sites include the periumbilical abdomen (at least 2 inches from the navel), the anterolateral thigh, and the lateral deltoid area. Rotate sites at each injection to prevent lipohypertrophy. The American Diabetes Association recommends site rotation within a region rather than random switching between regions, a principle that applies equally to peptide injection. [7]

Needle Selection

Standard U-100 insulin syringes come with 28-gauge, 29-gauge, or 31-gauge needles in 4 mm, 6 mm, or 8 mm lengths. For most adults with normal body habitus, a 31-gauge, 4 mm needle is sufficient to reach the subcutaneous layer while minimizing discomfort and tissue trauma.

Storage After Reconstitution

Reconstituted CJC-1295 stored at 2 to 8 °C in the dark remains stable and potent for up to 28 days when benzyl alcohol is present. Exposure to light accelerates oxidative degradation of the peptide backbone; keep the vial in its original box or wrapped in foil. Do not freeze reconstituted peptide, ice crystal formation physically disrupts the protein structure and causes irreversible aggregation. [5]

Lyophilized (unreconstituted) vials tolerate short-term room-temperature storage but should ideally remain refrigerated. Extended storage above 25 °C degrades lyophilized peptides over weeks to months; a 2021 review of lyophilized biologic stability confirmed a meaningful potency loss at 40 °C within 4 weeks for GHRH-class analogs. [8]

Safety Considerations and When to Contact Your Prescriber

CJC-1295 is not approved by the FDA as a finished drug product. All clinical use is off-label or investigational. Known adverse effects documented in the Teichman 2006 trial included flushing, headache, dizziness, and injection-site reactions in a minority of participants. Water retention and transient increases in blood glucose may occur secondary to GH elevation, clinically relevant in patients with diabetes or prediabetes. [1]

Patients on insulin or oral hypoglycemics should have their fasting glucose and HbA1c monitored at baseline and at 12 weeks. The Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency in Adults specifies that GH replacement therapy requires monitoring of IGF-1, fasting glucose, and symptom response every 1 to 2 months during the dose-titration phase, a framework applicable to GH secretagogue protocols. [9]

Contact your prescriber immediately if you observe:

• Cloudy or particulate reconstituted solution (do not inject)
• Severe injection-site swelling, redness, or warmth persisting beyond 48 hours
• Persistent headache or visual disturbance
• Unexplained hyperglycemia